CSBio CSBio

X
[{"orgOrder":0,"company":"Wockhardt","sponsor":"UK Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wockhardt snags Covid-19 Vaccine Manufacturing Deal From the UK Govt","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Wockhardt","sponsor":"U.S Government","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"India's Wockhardt Strikes Deal to Supply COVID-19 Vaccines to UK","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Jiangxi Jemincare Group Company","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Wockhardt and Jemincare Partner for Novel Respiratory Antibiotic Nafithromycin","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"INDIA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Wockhardt","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark Pharmaceuticals Inc., USA Continues to Expand Its Over-The-Counter (OTC) Portfolio With the Acquisition of Approved ANDAs From Wockhardt Limited","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Wockhardt Limited

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Glenmark has acquired the approved ANDAs for Famotidine Tablets USP, 10 mg and 20 mg, Cetirizine Hydrochloride Tablets USP, 5 mg and 10 mg, Lansoprazole DelayedRelease Capsules USP, 15 mg and Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1% from Wockhardt Limited.

            Lead Product(s): Famotidine

            Therapeutic Area: Gastroenterology Product Name: Famotidine- Generic

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition June 28, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the definitive agreement, Jemincare will be responsible for exclusive development and commercialization of the Nafithromycin in the select markets.

            Lead Product(s): Nafithromycin

            Therapeutic Area: Infections and Infectious Diseases Product Name: WCK 4873

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jiangxi Jemincare Group Company

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 26, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Wockhardt has reserved manufacturing capacity to allow for the supply of multiple vaccines to the UK Government in its fight against COVID19, including AZD1222, the vaccine co-invented by the University of Oxford and its spinout company, Vaccitech and licensed by AstraZeneca.

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase II/ Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: UK Government

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Wockhardt Ltd will supply millions of doses of multiple COVID-19 vaccines, including that being developed by AstraZeneca and Oxford University, under a deal with the UK government.

            Lead Product(s): ChAdOx1 nCoV-19

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD1222

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: U.S Government

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement August 03, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY